A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 in Patients With Chronic Hepatitis B
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs APG 1387 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 14 Oct 2019 Planned End Date changed from 30 Oct 2019 to 7 Feb 2020.
- 14 Oct 2019 Planned primary completion date changed from 30 Sep 2019 to 7 Feb 2020.
- 11 Jul 2018 Status changed from planning to recruiting.